Literature DB >> 29071852

[Huoxiang Zhengqi formulas for treatment of gastrointestinal type cold:a systematic review and Meta-analysis].

Hong-Jie Zhao1, Li-Ping Guo2, Feng-Wen Yang1, Ming-Yan Zhang1, Li-Shuag Zhang1, Zhi Liu1, Yue Li1, Zhao-Chen Ji1, Jun-Hua Zhang1, Wen-Ke Zheng1.   

Abstract

This systematic review aims to evaluate the efficacy and safety of Huoxiang Zhengqi formulas in treating gastrointestinal type cold. Seven electronic databases,including CNKI, WanFang Data, Vip, SinoMed, PubMed, Cochrane Library, Embase will be searched from the inception of the study until March 2017.All randomized controlled trials that evaluate the treatment of Huoxiang Zhengqi formulas for gastrointestinal type cold will be eligible. The methodological quality will be assessed using the Cochrane risk of bias tool for randomized clinical trials and Review Manager 5.3 software is used for analyzing the data.The results are: eight RCTs and 680 patients are included .Meta-analysis are performed according to the stratification of the treatment strategy. Eight studies report clinical efficacy, among them four studies show Huoxiang Zhengqi formulas are better than western medicine(RR and 95%,1.2[1.08, 1.33]), another four studies showHuoxiang Zhengqi formulas in conjunction with conventional treatment are better than conventional treatment(RR and 95%, 1.32[1.20,1.46]).About symptom remission rate, one study shows the treatment group effect is better than the control group from the following clinical symptoms:chills,fever,bowel diarrhea,the effect of treating sore throat itchy is same with western medicine treatment.No adverse reactions are found about Huoxiang Zhengqi formulas in this study.Current evidence shows that Huoxiangzhengqi formulas are better than Western medicine group and western medicine routine treatment group from clinical efficacy. Limited by the quantity and quality of studies, more large-scale and rigorously designed randomised controlled trials with large sample size are warranted to clarify the conclusions. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  Huoxiang Zhengqi ; gastrointestinal type cold ; meta analysis ; systematic review

Mesh:

Substances:

Year:  2017        PMID: 29071852     DOI: 10.19540/j.cnki.cjcmm.2017.0047

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  4 in total

1.  Effect of feeding Chinese herb medicine ageratum-liquid on intestinal bacterial translocations induced by H9N2 AIV in mice.

Authors:  Haoran Lu; Luxuan Zhang; Junfang Xiao; Che Wu; Huanmin Zhang; Yihu Chen; Zhengyong Hu; Wencheng Lin; Qingmei Xie; Hongxin Li
Journal:  Virol J       Date:  2019-02-21       Impact factor: 4.099

2.  The Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a study protocol for a double-blinded randomized controlled trial.

Authors:  Meiling Xuan; Xiaohui Guo; Hongyi Li; Ting Xie; Xiumei Mo; Zehuai Wen
Journal:  Trials       Date:  2021-01-19       Impact factor: 2.279

Review 3.  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.

Authors:  Wei Zhuang; Zheng Fan; Yanqi Chu; Haizheng Wang; Ying Yang; Li Wu; Nan Sun; Ge Sun; Yuqiao Shen; Xiaolan Lin; Guiming Guo; Shengyan Xi
Journal:  Front Pharmacol       Date:  2020-07-17       Impact factor: 5.810

4.  The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial.

Authors:  Xiaohui Guo; Meiling Xuan; Huan Zheng; Shumin Qin; Haomeng Wu; Shaogang Huang; Zehuai Wen
Journal:  Trials       Date:  2021-07-26       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.